- DESCRIPTION
- TABLE OF CONTENTS
- METHODOLOGY
- DOWNLOAD PDF
North America Human Microbiome Market By Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
USD 4.15 BN
MARKET SIZE, 2031
CAGR 32.2%
(2025-2031)
375
REPORT PAGES
414
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The North America Human Microbiome market, valued at US$0.43 billion in 2024, stood at US$0.78 billion in 2025 and is projected to advance at a resilient CAGR of 32.2% from 2025 to 2031, culminating in a forecasted valuation of US$4.15 billion by the end of the period. The North America human microbiome market growth is driven by improvements in novel microbiome-based products and therapeutic solutions due to partnerships between industry players and academic institutions. New startups in the US and Canada are driving innovation across microbiome therapeutics and diagnostics.
KEY TAKEAWAYS
-
By Region
The US human microbiome market made up 86.6% of the North American market in 2024.
-
By Product
Among product categories, microbiome drugs are expected to record the highest CAGR of 35.3%, largely due to a growing pipeline of microbiome-based therapeutics and greater funding for drug development.
-
By Route of Administration
From a route-of-administration perspective, the rectal route is projected to grow the fastest from 2025 to 2031.
-
By Disease
From a disease perspective, gastrointestinal disorders dominated the market in 2024, contributing 58.4% of total market.
-
Competitive Landscape
Several companies stand out as key players in the North America microbiome market, including International Flavors & Fragrances Inc., Seed Health, Inc., and Seres Therapeutics, all of which have built strong market presence and extensive product portfolios.
-
Competitive Landscape
Among startups and SMEs, companies such as AOBiome, Vedanta Biosciences, Inc., and Synlogic are emerging as promising leaders by carving out strong positions in niche application areas.
The human microbiome market in North America keeps growing steadily owing to the collaboration among biotechnology companies, academic institutions, and clinical research centers. The partnerships drive innovation in microbiome-based products and treatments. The presence of startups and medium sized enterprises, in the region speeds up research, product development and commercialization particularly in microbiome therapeutics, diagnostics and consumer health.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The revenue growth in the North America human microbiome market is shifting from traditional diagnostic and probiotic-based solutions toward advanced, technology-driven offerings. Emerging drivers include AI-enabled microbiome analytics, metagenomic sequencing, microbiome-informed therapeutics, and personalized nutrition programs. Clients, including hospitals, clinics, specialty care centres, and diagnostic laboratories, are focusing on integrating multi-omics platforms, standardized workflows, and high-throughput sequencing. These innovations are expected to enhance predictive accuracy, reduce operational costs, improve patient stratification, and increase reproducibility, which is ultimately accelerating microbiome-based diagnostic and therapeutic development
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
-
Rising prevalence of chronic and lifestyle-related diseases
-
Advancements in sequencing and bioinformatics technologies
RESTRAINTS
Impact
Level
-
Lack of standardized protocols and regulatory challenges
-
High cost of microbiome-based therapies
OPPORTUNITIES
Impact
Level
-
Increasing demand for personalized medicine
-
Emergence of postbiotics
CHALLENGES
Impact
Level
-
Slow patient adoption of microbiome-based therapies
-
Complexities involved in development of microbiome therapies
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
In North America, there are rising rates of obesity, diabetes, autoimmune disorders, and inflammation of the bowel. All these medical conditions have been increasing over a decade. As a result, there is more focus on microbiome-based therapies. Medical researchers and practitioners have increasingly focused on the microbiome as a potential source of support for medical practice and disease prevention.
Limited protocol standardization appears to be one of the major challenges in the human microbiome within North America, as there are no standards and consistency that are applicable for the development of microbiome-based drugs. All procedures, from sample collection to processing as well as analysis, differ considerably, making it difficult for development and consistency. Moreover, standards on microbiome therapies appear to still be taking form. As a result, there appear to be considerable delays within companies seeking to capitalize on these developments.
The medical sector is increasingly shifting towards more personalized treatment, such as microbiome-based therapies. By knowing an individual’s particular microbiome profile, it becomes possible to personalize treatments to improve the prevention and treatment of disease. Personalized medicine leads to better responses with fewer side effects. There is more drive towards developing microbiome therapies for immune, metabolic, and gastrointestinal disorders.
The market growth of microbiome therapies remains slow, as many patients and some medical professionals are not aware of the therapy functions. Clinical data are still emerging, and inconsistencies exist with product formulations. Personalized therapies may have more complex treatment regimens, which could delay their general acceptance. All these considerations make it difficult for microbiome therapies to remain mainstream.
NORTH AMERICA HUMAN MICROBIOME MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Ostia Sciences announced a collaboration with Expert’Biome (a CDMO by Lallemand) to support process development and clinical-grade production for an oral care probiotic program | Demonstrated incremental build-out of capacity via CDMO partnerships instead of investing in new facilities | Accelerated time to clinic by leveraging an established GMP partner |Reduced upfront capital burden for smaller biotech players |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The North America human microbiome market ecosystem consists of manufacturers (ExeGi Pharma, SeedHealth, ResBiotic, Seres Therapeutics), regulatory bodies (U.S. FDA, Government of Canada), raw material suppliers (ATCC, ADM, OpenBiome), and end users (Duke Health, Boston Children’s Hospital, Cambridge University Hospitals). Microbial strains, culture media, and reagents are developed into therapeutics, probiotics, and diagnostics. End users drive demand for innovative, personalized microbiome-based solutions, while manufacturers and suppliers provide high-quality products. Collaboration across the ecosystem supports research, clinical translation, and market growth.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
In 2024, microbiome supplements led the North America human microbiome market fueled by consumer interest in probiotics, prebiotics and synbiotics targeting digestive health, immune support and general well-being. These items are readily available over the counter, bolstered by increasing recognition of gut health connections and trends in care.
The oral form of administration was the leading form present within the North America human microbiome drugs and supplement market in 2024. The oral form comes in various forms, such as capsules, powders, and liquids, which are convenient and more affordable modes of consumption. Moreover, they provide an easier alternative for the administration of probiotics and prebiotics.
In 2024, the market for the human microbiome in North America is driven by gastrointestinal disorders due to the predominant link shown between an imbalance of gut microbiomes and gastrointestinal disorders. The gastrointestinal disorders.
REGION
US to be fastest-growing country in North America Human Microbiome Market during forecast period
The US human microbiome market is expected to register the highest CAGR during the forecast period driven by companies and research initiatives, the increasing prevalence of chronic diseases, government initiatives and growing investments in developing microbiome-based therapeutics. Leading firms such as BIOHM Health, Seed Health, Inc., Seres Therapeutics, Inc., and Vedanta Biosciences, Inc. are developing advanced therapies and health solutions based on microbiome science.
NORTH AMERICA HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX
In the human microbiome market matrix, International Flavors & Fragrances Inc. leads with a strong market presence and comprehensive product portfolio, demonstrating a strong commitment to advancing microbiome health solutions globally. Pendulum is gaining traction with specialized solutions and expanding footprints, particularly in gut-health and overall well-being.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- International Flavors & Fragrances Inc. (US)
- Seed Health, Inc. (US)
- Seres Therapeutics (US)
- Pendulum (US)
- BioHM Health Inc. (US)
- Resbiotic (US)
- Infinant Health Inc. (US)
- ExeGi Pharma LLC (US)
- Finch Therapeutics Group, Inc. (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 0.43 Billion |
| Market Forecast in 2031 (Value) | USD 4.15 Billion |
| Growth Rate | CAGR of 32.2% from 2025-2031 |
| Years Considered | 2023-2031 |
| Base Year | 2024 |
| Forecast Period | 2025-2031 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Countries Covered | US, Canada |
| Parent & Related Segment Reports |
Human Microbiome Market Europe Human Microbiome Market Human Microbiome Manufacturing Services Market Asia Pacific Human Microbiome Market Human Microbiome Drugs Market |
WHAT IS IN IT FOR YOU: NORTH AMERICA HUMAN MICROBIOME MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| North America Human Microbiome Market, By Distribution Channel | Market size & forecast for human microbiome market based on type of distribution - Prescription-based Products and OTC Products | Split of Supplements into clinical (prescription/FSMP/medical foods) vs. consumer OTC (wellness probiotics, synbiotics) |
| North America Human Microbiome Diagnostics Market, By Type | Market size & forecast for human microbiome market based on type of diagnostics - microbiome test and companion diagnostics | Diagnostic TAM assessment |
RECENT DEVELOPMENTS
- February 2025 : GluCare Health collaborated with Pendulum Therapeutics to evaluate the impact of Pendulum Glucose Control, a probiotic, on blood sugar levels, weight management, and overall metabolic health
- October 2024 : BIOHM Health, Inc. partnered with ADM to launch Vivifem, a data-driven microbiome formulation for women aged 40-65. Developed using BIOHM's Symbiont platform, the formula combines prebiotics, probiotics, and postbiotics to target microbiome imbalances associated with aging
- April 2023 : The US Food and Drug Administration approved VOWST (live-brpk), which is the first fecal microbiota transplant product meant to be taken orally. VOWST has been given the green light for preventing Clostridioides difficile (C. difficile) Infection recurrence in individuals aged 18 and above, following antibacterial treatment for recurrent CDI
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
15
2
EXECUTIVE SUMMARY
3
PREMIUM INSIGHTS
4
MARKET OVERVIEW
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.2
RESTRAINTS
4.2.3
OPPORTUNITIES
4.2.4
CHALLENGES
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF SUPPLIERS
5.1.4
BARGAINING POWER OF BUYERS
5.1.5
INTENSITY OF COMPETITION RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN NORTH AMERICA HEALTHCARE INDUSTRY
5.2.4
TRENDS IN NORTH AMERICA PHARMA INDUSTRY
5.3
VALUE CHAIN ANALYSIS
5.4
ECOSYSTEM ANALYSIS
5.5
PRICING ANALYSIS
5.5.1
AVERAGE SELLING PRICE OF KEY PLAYERS, BY END-USE INDUSTRY,
5.5.2
AVERAGE SELLING PRICE TREND, BY PRODUCT, 2022-2024
5.5.3
AVERAGE SELLING PRICE TREND, BY COUNTRY, 2022-2024
5.6
KEY CONFERENCES & EVENTS, 2025-2026
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.7.1
DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
5.8
INVESTMENT AND FUNDING SCENARIO
5.9
CASE STUDY ANALYSIS
5.10
IMPACT OF 2025 US TARIFF ON NORTH AMERICA HUMAN MICROBIOME MARKET
5.10.1
INTRODUCTION
5.10.2
KEY TARIFF RATES
5.10.3
PRICE IMPACT ANALYSIS
5.10.4
IMPACT ON COUNTRY
5.10.4.1
US
5.10.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY TECHNOLOGIES
6.1.1
WHOLE-GENOME SEQUENCING
6.1.2
16S RNA SEQUENCING METHOD
6.1.3
NANOPORE SEQUENCING
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
METATRANSCRIPTOMICS
6.2.2
METAGENOMICS
6.2.3
METABOLOMICS
6.3
ADJACENT TECHNOLOGIES
6.3.1
SAMPLE PREPARATION
6.3.2
DATA ANALYSIS
6.3.3
LIBRARY SYNTHESIS
6.4
TECHNOLOGY ROADMAP
6.5
PATENT ANALYSIS
6.6
FUTURE APPLICATIONS
6.7
IMPACT OF AI/ GEN AI ON NORTH AMERICA HUMAN MICROBIOME MARKET
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
BEST PRACTICES IN AI-ENABLED HUMAN MICROBIOME WORKFLOWS
6.7.3
CASE STUDIES OF AI ADOPTION
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.5
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED MICROBIOME ANALYTICS SOLUTIONS
7
REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
7.1.2
INDUSTRY STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
INTRODUCTION
8.2
DECISION-MAKING PROCESS
8.3
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.3.2
BUYING CRITERIA
8.4
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
NORTH AMERICA HUMAN MICROBIOME MARKET, BY PRODUCT, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
9.1
INTRODUCTION
9.2
HUMAN MICROBIOME DRUGS
9.3
HUMAN MICROBIOME SUPPLEMENTS
9.3.1
PROBIOTICS
9.3.2
PREBIOTICS
9.3.3
SYNBIOTICS
9.4
MICROBIOME DIAGNOSTICS
10
NORTH AMERICA HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
10.1
INTRODUCTION
10.2
BACTERIAL CONSORTIA TRANSPLANT (BCT)/FECAL MICROBIOTA TRANSPLANT (FMT)
10.3
LIVE BACTERIA PRODUCTS
10.4
OTHER PRODUCT TYPES
11
NORTH AMERICA HUMAN MICROBIOME MARKET, BY DISEASE, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
11.1
INTRODUCTION
11.2
INFECTIOUS DISEASES
11.3
GASTROINTESTINAL DISEASES
11.4
ENDOCRINE & METABOLIC DISORDERS
11.5
OTHER DISEASES
12
NORTH AMERICA HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
12.1
INTRODUCTION
12.2
ORAL ROUTE OF ADMINISTRATION
12.3
RECTAL ROUTE OF ADMINISTRATION
13
NORTH AMERICA HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
13.1
INTRODUCTION
13.2
STRAIN DEVELOPMENT & OPTIMIZATION
13.3
FERMENTATION & DOWNSTREAM PROCESSING
13.4
FORMULATION & FILL/FINISH
13.5
OTHER SERVICES
14
NORTH AMERICA HUMAN MICROBIOME MARKET, BY END USER, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
14.1
INTRODUCTION
14.2
HOSPITALS & CLINICS
14.3
LONG-TERM CARE FACILITIES
14.4
OTHER END USERS
15
NORTH AMERICA HUMAN MICROBIOME MARKET, BY COUNTRY, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
15.1
INTRODUCTION
15.2
US
15.3
CANADA
16
COMPETITIVE LANDSCAPE
16.1
INTRODUCTION
16.2
KEY PLAYERS’ STRATEGIES/RIGHT TO WIN (JANUARY 2022 – NOVEMBER 2025)
16.3
REVENUE ANALYSIS, 2020-2024
16.4
MARKET SHARE ANALYSIS,
16.5
COMPANY EVALUATION MATRIX: KEY PLAYERS,
16.5.1
STARS
16.5.2
EMERGING LEADERS
16.5.3
PERVASIVE PLAYERS
16.5.4
PARTICIPANTS
16.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
16.5.5.1
COMPANY FOOTPRINT
16.5.5.2
COUNTRY FOOTPRINT
16.5.5.3
PRODUCT FOOTPRINT
16.5.5.4
TYPE FOOTPRINT
16.5.5.5
DISEASE FOOTPRINT
16.6
COMPANY EVALUATION MATRIX: START-UPS/SMES,
16.6.1
PROGRESSIVE COMPANIES
16.6.2
RESPONSIVE COMPANIES
16.6.3
DYNAMIC COMPANIES
16.6.4
STARTING BLOCKS
16.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
16.6.5.1
DETAILED LIST OF KEY STARTUPS/ SMES
16.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
16.7
COMPETITIVE SCENARIO
16.7.1
PRODUCT/SERVICE LAUNCHES
16.7.2
DEALS
16.7.3
EXPANSIONS
16.8
BRAND COMPARISON
16.8.1
INTERNATIONAL FLAVOURS & FRAGRANCES INC.
16.8.2
SEED HEALTH INC.
16.8.3
SERES THERAPEUTICS
16.9
COMPANY VALUATION AND FINANCIAL METRICS
17
COMPANY PROFILES*
IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE NORTH AMERICA HUMAN MICROBIOME MARKET LANDSCAPE
17.1
KEY PLAYERS
17.1.1
INTERNATIONAL FLAVORS & FRAGRANCES INC.
17.1.1.1
BUSINESS OVERVIEW
17.1.1.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.1.3
MNM VIEW
17.1.1.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.1.3.2
STRATEGIC CHOICES
17.1.1.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.2
SEED HEALTH, INC.
17.1.2.1
BUSINESS OVERVIEW
17.1.2.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.2.3
MNM VIEW
17.1.2.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.2.3.2
STRATEGIC CHOICES
17.1.2.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.3
SERES THERAPEUTICS
17.1.3.1
BUSINESS OVERVIEW
17.1.3.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.3.3
MNM VIEW
17.1.3.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.3.3.2
STRATEGIC CHOICES
17.1.3.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.4
BIOHM TECHNOLOGIES
17.1.4.1
BUSINESS OVERVIEW
17.1.4.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.4.3
MNM VIEW
17.1.4.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.4.3.2
STRATEGIC CHOICES
17.1.4.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.5
PENDULUM
17.1.5.1
BUSINESS OVERVIEW
17.1.5.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.5.3
MNM VIEW
17.1.5.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.5.3.2
STRATEGIC CHOICES
17.1.5.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.6
RESBIOTIC
17.1.6.1
BUSINESS OVERVIEW
17.1.6.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.6.3
RECENT DEVELOPMENTS
17.1.7
INFINANT HEALTH INC.
17.1.7.1
BUSINESS OVERVIEW
17.1.7.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.7.3
RECENT DEVELOPMENTS
17.1.8
FINCH THERAPEUTICS GROUP, INC.
17.1.8.1
BUSINESS OVERVIEW
17.1.8.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.8.3
RECENT DEVELOPMENTS
17.1.9
EXEGI PHARMA
17.1.9.1
BUSINESS OVERVIEW
17.1.9.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.9.3
RECENT DEVELOPMENTS
18
RESEARCH METHODOLOGY
18.1
RESEARCH DATA
18.1.1
SECONDARY DATA
18.1.1.1
KEY SOURCES OF SECONDARY DATA
18.1.1.2
KEY OBJECTIVES OF SECONDARY DATA
18.1.2
PRIMARY DATA
18.1.2.1
BREAKDOWN OF PRIMARIES
18.1.2.2
KEY OBJECTIVES OF PRIMARY RESEARCH
18.2
MARKET SIZE ESTIMATION
18.2.1
NORTH AMERICA HUMAN MICROBIOME MARKET SIZE ESTIMATION,
18.2.1.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
18.2.1.2
MNM REPOSITORY ANALYSIS
18.2.1.3
SECONDARY ANALYSIS
18.2.1.4
PRIMARY RESEARCH
18.2.1.4.1
INSIGHTS FROM PRIMARY EXPERTS
18.2.2
SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
18.3
MARKET GROWTH RATE PROJECTIONS
18.4
DATA TRIANGULATION
18.5
FACTOR ANALYSIS
18.6
RESEARCH LIMITATIONS & RISK ASSESSMENT
18.7
RISK ANALYSIS
19
APPENDIX
19.1
DISCUSSION GUIDE
19.2
KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3
AVAILABLE CUSTOMIZATIONS
19.4
RELATED REPORTS
19.5
AUTHOR DETAILSS
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the North America Human Microbiome Market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The North America market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include World Health Organization (WHO), Human Microbiome Project (HMP), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), Food and Drug Administration (FDA), ClinicalTrials.gov, Annual Reports, SEC Filings, Investor Presentations, Research Journals, Press Releases, and financial statements. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative & quantitative information and assess the prospects of the market. Various primary sources from both the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate & validate the total size of the North America Human Microbiome Market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
The human microbiome encompasses the collective genetic material of diverse microorganisms residing within the human body, known as the metagenome. This includes bacteria, fungi, protozoans, non-living viruses, and various single-celled organisms. These microorganisms play a crucial role in human physiology, influencing metabolic and immune functions. Found within human tissues, the microbiome is a focal point of research for medical advancements and analytical techniques. It is applied in probiotics, prebiotics, pharmaceuticals, and therapeutic systems to address conditions such as diabetes, obesity, and cancer, as well as a range of metabolic, gastrointestinal, neurological, central nervous system, and autoimmune disorders.
The study provides an in-depth analysis of the North America Human Microbiome Market based on contemporary market trends and developments, and its potential growth from 2025 to 2031. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key Human Microbiome service providers.
Stakeholders
- Manufacturers and Distributors of Human Microbiome Products
- Pharmaceutical and Biotechnology Companies
- Market Research and Consulting Firms
- R&D Centers
- Researchers and Scientists
- Academic & Research Institutes
- Hospitals & Clinics
- Long-term Care Centers
- Specialty Care Centers
- Outpatient Care Centers
Report Objectives
- To define, describe, and forecast the North America Human Microbiome Market based on products, disease, drugs & supplements type, drugs & supplements route of administration, end user, manufacturing services and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall North America Human Microbiome Market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To strategically profile the key players in the North America Human Microbiome Market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the North America Human Microbiome Market
- To benchmark players within the North America Human Microbiome Market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
⚡ Growth Signals
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the North America Human Microbiome Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Still Researching the
North America Human Microbiome Ecosystem?
See the competitors, opportunities, and growth signals shaping it - instantly.
Generate 15+ consulting-grade strategic insights tailored to your growth question.
Explore North America Human Microbiome Intelligence
Powered by 17 years of MarketsandMarkets intelligence
